🇺🇸 FDA
Pipeline program

METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE HYDROGEN SUCCINATE, METHYLPREDNISOLONE , METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE

APHP230821

Phase 2 small_molecule active

Quick answer

METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE HYDROGEN SUCCINATE, METHYLPREDNISOLONE , METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE for NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials